Aurora Kinase Inhibitors: the Dawn of a New Approach to Cancer.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c24163) has announced the addition of Aurora Kinase Aurora kinases are serine/threonine kinases that are essential for cell proliferation. The enzyme helps the dividing cell share its genetic materials with its daughter cells. inhibitors - The dawn of a new approach to cancer to their offering. Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle mitotic spindle n. The fusiform figure characteristic of a dividing cell, consisting of microtubules, some of which become attached to each chromosome at its centromere and provide the mechanism for chromosomal movement. formation as exemplified by the alkaloids alkaloids, n alkaline phytochemicals that contain nitrogen in a heterocyclic ring structure. They can have powerful pharmacological effects and are more often used in traditional medicine than in herbal treatments. . Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell cycle from the G2/M check point all the way through to the mitotic mitotic pertaining to mitosis. mitotic activity degree to which a cell population is proliferating; used as an index of tumor aggression. checkpoint and late mitosis. Aurora Kinase Inhibitors: The dawn of a new approach to cancer was written as a target evaluation/drug development update report. This analysis was intended to provide a framework for all organizations considering entry into this exciting field or those already in the field but who require competitive intelligence within the area. The report: --Introduces the Aurora kinases --Analyzes the proof of concept supporting the development of aurora kinase inhibitors for the treatment of cancer --Discusses mechanism of action --Evaluates drugs in development --Provides strategic guidance on kinase selectivity --Discusses the promise and risks of kinase inhibitors --Offers competitive intelligence discussing how Aurora kinase inhibitors would fit into the current oncology treatment area. The report compares this class with existing and emerging classes and evaluates the part that Aurora kinase inhibitors could play in the combinatorial approach to cancer Brief view of Contents: 1. Summary 2. Background 3. Eukaryotic eukaryotic /eu·kary·ot·ic/ (u?kar-e-ot´ik) pertaining to a eukaryon or to a eukaryote. eukaryotic pertaining to eukaryosis. eukaryotic cells see cell. Chromosome Packaging 4. HDAC HDAC Histone Deacetylase (biochemistry) HDAC Heavy Duty Air Cylinder : An Early History 5. Chromatin chromatin: see chromosome. remodeling remodeling /re·mod·el·ing/ (re-mod´el-ing) reorganization or renovation of an old structure. bone remodeling in transcriptional control 6. The Mammalian HDAC enzymes 7. The HDACs and transcriptional silencing - molecular strategies for achieving transcriptional control 8. HDAC:protein interactions 9. Post-translational modifications in the control of HDAC activity 10. Biological consequences of HDAC inhibition 12. Profiles of HDAC inhibitors in clinical development 13. Strategic & Competitive Analysis Apoptosis Stimulators For more information visit http://www.researchandmarkets.com/reports/c24163 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion